Provided by Tiger Fintech (Singapore) Pte. Ltd.

BridgeBio Pharma, Inc.

41.14
+1.363.42%
Volume:2.86M
Turnover:116.87M
Market Cap:7.81B
PE:-11.64
High:41.36
Open:39.95
Low:39.63
Close:39.78
Loading ...
May 10, 2022

Major Issues Report

8-K - Current report
May 05, 2022

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Feb 25, 2022

Annual Report

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Feb 25, 2022

Employee Stock Ownership

S-8 - Securities to be offered to employees in employee benefit plans
Feb 24, 2022

Major Issues Report

8-K - Current report
Feb 15, 2022

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 14, 2022

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 09, 2022

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Dec 27, 2021

Major Issues Report

8-K - Current report
Dec 16, 2021

Major Issues Report

8-K - Current report
Dec 07, 2021

Statement Of Changes In Beneficial Ownership

4 - Statement of changes in beneficial ownership of securities
Dec 07, 2021

Statement Of Changes In Beneficial Ownership

4 - Statement of changes in beneficial ownership of securities
Dec 06, 2021

Statement Of Changes In Beneficial Ownership

4 - Statement of changes in beneficial ownership of securities
Dec 06, 2021

Statement Of Changes In Beneficial Ownership

4 - Statement of changes in beneficial ownership of securities
Nov 18, 2021

Statement Of Changes In Beneficial Ownership

4 - Statement of changes in beneficial ownership of securities
Nov 18, 2021

Statement Of Changes In Beneficial Ownership

4 - Statement of changes in beneficial ownership of securities
Oct 26, 2021

Major Issues Report

8-K - Current report
Aug 23, 2021

Major Issues Report

8-K - Current report
Aug 13, 2021

Major Issues Report

8-K - Current report
Aug 05, 2021

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]